Abstract
Nuclear factor (NF)-κB is regarded as one of the most important transcription factors and plays an essential role in the transcriptional activation of pro-inflammatory cytokines, cell proliferation and survival. NF-κB can be activated via two distinct NF-κB signal transduction pathways, the so-called canonical and non-canonical pathways, and has been demonstrated to play a key role in a wide range of inflammatory diseases and various types of cancer. Much effort has been put in strategies to inhibit NF-κB activation, for example by the development of pharmacological compounds that selectively inhibit NF-κB activity and therefore would be beneficial for immunotherapy of transplantation, autoimmune and allergic diseases, as well as an adjuvant approach in patients treated with chemotherapy for cancer. Gene therapy targeting NF-κB is a promising new strategy with the potential of long-term effects and has been explored in a wide variety of diseases, ranging from cancer to transplantation medicine and autoimmune diseases. In this review we discuss recent progress made in the development of NF-κB targeted gene therapy and the evolution towards clinical application.
Keywords: Gene therapy, NF-κB, signal transduction, siRNA, decoy oligodeoxynucleotides, adenovirus, adeno-associated virus, adoptive transfer
Current Gene Therapy
Title: Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Volume: 9 Issue: 3
Author(s): Sander W. Tas, Margriet J.B.M. Vervoordeldonk and Paul P. Tak
Affiliation:
Keywords: Gene therapy, NF-κB, signal transduction, siRNA, decoy oligodeoxynucleotides, adenovirus, adeno-associated virus, adoptive transfer
Abstract: Nuclear factor (NF)-κB is regarded as one of the most important transcription factors and plays an essential role in the transcriptional activation of pro-inflammatory cytokines, cell proliferation and survival. NF-κB can be activated via two distinct NF-κB signal transduction pathways, the so-called canonical and non-canonical pathways, and has been demonstrated to play a key role in a wide range of inflammatory diseases and various types of cancer. Much effort has been put in strategies to inhibit NF-κB activation, for example by the development of pharmacological compounds that selectively inhibit NF-κB activity and therefore would be beneficial for immunotherapy of transplantation, autoimmune and allergic diseases, as well as an adjuvant approach in patients treated with chemotherapy for cancer. Gene therapy targeting NF-κB is a promising new strategy with the potential of long-term effects and has been explored in a wide variety of diseases, ranging from cancer to transplantation medicine and autoimmune diseases. In this review we discuss recent progress made in the development of NF-κB targeted gene therapy and the evolution towards clinical application.
Export Options
About this article
Cite this article as:
Tas W. Sander, Vervoordeldonk J.B.M. Margriet and Tak P. Paul, Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer, Current Gene Therapy 2009; 9 (3) . https://dx.doi.org/10.2174/156652309788488569
DOI https://dx.doi.org/10.2174/156652309788488569 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on JAK Inhibitors
Current Medicinal Chemistry Role of Positron Emission Tomography for Central Nervous System Involvement in Systemic Autoimmune Diseases: Status and Perspectives
Current Medicinal Chemistry Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry Mechanism by which Regulatory Rheumatoid Factor Prevents Experimental Autoimmune Encephalomyelitis
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) Some Important Dietary Polyphenolic Compounds: An Anti-inflammatory and Immunoregulatory Perspective
Mini-Reviews in Medicinal Chemistry Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Regulatory T Cells in Severe Drug Eruptions
Current Immunology Reviews (Discontinued) Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Biologics in Autoimmune Diseases)
Current Pharmaceutical Biotechnology Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a
Protein & Peptide Letters Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design